Braxia Scientific to Commence Landmark Clinical Trial to Conduct Canada’s First Multiple-Dose Psilocybin Clinical Trial for Treatment Resistant Depression
First multiple-dose psilocybin clinical trial will be conducted at Braxia Health’s Canadian Rapid Treatment Centers Trial will include adults with treatment-resistant depression and will also enroll adults who have previously tried electroconvulsive therapy and/or intravenous ketamine TORONTOAug. 27, 2021 “This will be the broadest study of its kind,” said Dr. Joshua Rosenblat , the trial’s principal investigator […]
